Zacks: Brokerages Anticipate XOMA Corp (XOMA) to Announce -$0.38 EPS

Share on StockTwits

Wall Street analysts expect XOMA Corp (NASDAQ:XOMA) to post earnings per share (EPS) of ($0.38) for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for XOMA’s earnings. The lowest EPS estimate is ($0.40) and the highest is ($0.35). XOMA reported earnings of $1.98 per share in the same quarter last year, which would indicate a negative year over year growth rate of 119.2%. The business is scheduled to announce its next quarterly earnings report on Monday, November 5th.

On average, analysts expect that XOMA will report full year earnings of ($1.14) per share for the current fiscal year, with EPS estimates ranging from ($1.42) to ($0.70). For the next financial year, analysts forecast that the business will post earnings of ($0.82) per share, with EPS estimates ranging from ($1.37) to ($0.44). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for XOMA.

XOMA (NASDAQ:XOMA) last issued its quarterly earnings results on Tuesday, August 7th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.03). XOMA had a net margin of 43.55% and a return on equity of 379.39%. The firm had revenue of $2.26 million for the quarter, compared to the consensus estimate of $4.57 million.

Several equities analysts recently issued reports on XOMA shares. Wedbush restated an “outperform” rating on shares of XOMA in a research note on Monday, September 17th. Zacks Investment Research lowered XOMA from a “buy” rating to a “hold” rating in a research note on Saturday, July 21st. S&P Equity Research lowered their price target on XOMA from $18.74 to $16.26 in a research note on Tuesday, August 14th. ValuEngine lowered XOMA from a “hold” rating to a “sell” rating in a research note on Friday, September 7th. Finally, HC Wainwright restated a “buy” rating and set a $49.00 price target on shares of XOMA in a research note on Friday, September 21st. Two analysts have rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $31.32.

Several hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. grew its stake in shares of XOMA by 151.6% in the 2nd quarter. BlackRock Inc. now owns 448,856 shares of the biotechnology company’s stock valued at $9,373,000 after purchasing an additional 270,437 shares during the period. Acadian Asset Management LLC grew its stake in shares of XOMA by 70.4% in the 2nd quarter. Acadian Asset Management LLC now owns 96,051 shares of the biotechnology company’s stock valued at $2,006,000 after purchasing an additional 39,672 shares during the period. Northern Trust Corp grew its stake in shares of XOMA by 308.6% in the 2nd quarter. Northern Trust Corp now owns 68,200 shares of the biotechnology company’s stock valued at $1,424,000 after purchasing an additional 51,510 shares during the period. Spark Investment Management LLC grew its stake in shares of XOMA by 16.6% in the 2nd quarter. Spark Investment Management LLC now owns 52,100 shares of the biotechnology company’s stock valued at $1,087,000 after purchasing an additional 7,400 shares during the period. Finally, Bank of New York Mellon Corp grew its stake in shares of XOMA by 50.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 35,661 shares of the biotechnology company’s stock valued at $745,000 after purchasing an additional 12,002 shares during the period. Institutional investors own 43.60% of the company’s stock.

Shares of XOMA opened at $15.30 on Friday. XOMA has a 12-month low of $14.61 and a 12-month high of $37.25. The company has a debt-to-equity ratio of 3.06, a quick ratio of 12.46 and a current ratio of 12.46. The stock has a market cap of $147.36 million, a P/E ratio of 15.61 and a beta of 2.51.

About XOMA

XOMA Corporation engages in the discovery, development, and licensing of therapeutic antibodies in the United States, Europe, and the Asia Pacific. The company has a portfolio of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development.

Featured Story: What is the NASDAQ?

Get a free copy of the Zacks research report on XOMA (XOMA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for XOMA (NASDAQ:XOMA)

Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply